Literature DB >> 7904604

Roles of v-erbA homodimers and heterodimers in mediating dominant negative activity by v-erbA.

P M Yen1, M Ikeda, J H Brubaker, M Forgione, A Sugawara, W W Chin.   

Abstract

v-erbA, a viral oncogenic homolog of thyroid hormone receptor (TR), blocks the effect of T3 in TR-mediated transcription. The mechanism(s) for this dominant negative effect by v-erbA on TRs is unknown but may involve competition between v-erbA and TR-containing complexes for binding to thyroid hormone response elements (TREs) and/or protein-protein interactions between v-erbA and TR. To investigate these potential mechanisms, we used the electrophoretic mobility shift assay to compare in vitro translated v-erbA and TR alpha binding to two TREs-chick lysozyme TRE (F2) and direct repeat TRE (DR4). v-erbA bound as a homodimer to these TREs, whereas TR alpha bound as a homodimer and monomer. T3 decreased TR alpha homodimer binding to the TREs as we reported previously; however, surprisingly, high concentrations of T3 (10(-6) M) also decreased v-erbA homodimer binding to the TREs. Additionally, v-erbA formed heterodimers with nuclear proteins such as retinoid X receptor and T3 receptor auxiliary protein as well as with TR alpha. These dimers remained bound to DNA in the presence of T3. Finally, v-erbA could not mediate ligand-dependent transcriptional activation even at 10(-6) M T3 but could block ligand-dependent TR-mediated transactivation in co-transfection experiments. v-erbA also exhibited differential dominant negative activity on F2 and DR4 suggesting that half-site sequence and/or orientation may influence v-erbA-dominant negative activity. In sum, there are multiple v-erbA complexes that bind to TREs in the presence of T3, which all may contribute to v-erbA's dominant negative effect on TR-mediated transcription by competing with TR-containing complexes for binding to TREs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7904604

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Thyroid hormone receptors and cancer.

Authors:  Won Gu Kim; Sheue-yann Cheng
Journal:  Biochim Biophys Acta       Date:  2012-04-06

2.  Multiple mutations contribute to repression by the v-Erb A oncoprotein.

Authors:  Sangho Lee; Martin L Privalsky
Journal:  Oncogene       Date:  2005-10-13       Impact factor: 9.867

3.  A Purkinje cell protein-2 intronic thyroid hormone response element binds developmentally regulated thyroid hormone receptor-nuclear protein complexes.

Authors:  S G Hagen; R J Larson; K A Strait; J H Oppenheimer
Journal:  J Mol Neurosci       Date:  1996       Impact factor: 3.444

4.  Myb-Ets fusion oncoprotein inhibits thyroid hormone receptor/c-ErbA and retinoic acid receptor functions: a novel mechanism of action for leukemogenic transformation by E26 avian retrovirus.

Authors:  A Rascle; N Ferrand; O Gandrillon; J Samarut
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

5.  Modeling follicular thyroid cancer for future therapies.

Authors:  Xuguang Zhu; Sheue-Yann Cheng
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

6.  Thyroid hormone promotes the phosphorylation of STAT3 and potentiates the action of epidermal growth factor in cultured cells.

Authors:  H Y Lin; A Shih; F B Davis; P J Davis
Journal:  Biochem J       Date:  1999-03-01       Impact factor: 3.857

7.  Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms.

Authors:  O Araki; H Ying; X G Zhu; M C Willingham; S Y Cheng
Journal:  Mol Endocrinol       Date:  2009-01-08

8.  Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma.

Authors:  X-G Zhu; L Zhao; M C Willingham; S-Y Cheng
Journal:  Oncogene       Date:  2010-01-11       Impact factor: 9.867

Review 9.  Thyroid hormone actions in liver cancer.

Authors:  Sheng-Ming Wu; Wan-Li Cheng; Crystal D Lin; Kwang-Huei Lin
Journal:  Cell Mol Life Sci       Date:  2012-09-06       Impact factor: 9.261

10.  Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA.

Authors:  C Barlow; B Meister; M Lardelli; U Lendahl; B Vennström
Journal:  EMBO J       Date:  1994-09-15       Impact factor: 11.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.